Efta Triastuti , Dadang Hendrawan, Muhammad Saifurrohman
Background: β-blocker is an established therapeutic strategy for stage C systolic heart failure based on the American Heart Association guideline, nonetheless limited studies analyzed the role of β-blocker primarily Bisoprolol adding to ACE inhibitor and furosemide combination on the left ventricular function in systolic heart failure patients.
Objectives: This study was designed to analyze the role of Bisoprolol adding to ACE inhibitor and furosemide combination on the ventricular function in patients with systolic heart failure particularly on ejection fraction and quality of life.
Subjects & Methods: 40 to 80 years old ambulatory patients (N=30) at Dr. Saiful Anwar General Hospital Malang diagnosed as stage C systolic heart failure receiving optimum dose of inhibitor ACE and furosemide combination for at least 2 months. Before Bisoprolol was added, the ejection fraction and the quality of life was observed to assess the baseline left ventricular function then re-observed after 3 months.
Results: After the adding of Bisoprolol, there were significant differences in ejection fraction (measured by echocardiography) and quality of life (measured by Minnesota quality of life living with heart failure questionnaire) with both P value equal to 0,000 (95% Confidence Interval).
Conclusions: The adding of Bisoprolol to ACE inhibitor and Furosemide combination seems to improve the left ventricular function in stage C systolic heart failure patients particularly on ejection fraction and quality of life measurements
